Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ARNALDO ISA

NPI
1952390452
CMS profile
134407
Location
MAITLAND, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$3,559.32

195 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,547.89 193
Education $11.43 2

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 195 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ARNALDO ISA

NPI 1952390452 · CMS profile ID 134407

MAITLAND, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 195 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1952390452?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ARNALDO ISA, NPI 1952390452, CMS profile ID 134407. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 195 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1952390452?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). ARNALDO ISA, NPI 1952390452, CMS profile ID 134407. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 195 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1952390452?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
ARNALDO ISA, NPI 1952390452, CMS profile ID 134407, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 195 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1952390452?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

195 matching records · $3,559.32 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 195 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 195.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $3.5509/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997536431 CMS
ABBVIE INC. $17.1309/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997536429 CMS
Biogen, Inc. $16.5909/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012277081 CMS
MDD US Operations, LLC $20.4409/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052879121 CMS
Teva Pharmaceuticals USA, Inc. $22.2909/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056670331 CMS
ABBVIE INC. $17.1409/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997536427 CMS
GENZYME CORPORATION $23.0809/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049802183 CMS
ARGENX US, INC. $0.9109/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060431347 CMS
ARGENX US, INC. $26.3709/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060431349 CMS
Genentech USA, Inc. $32.3809/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040304443 CMS
ABBVIE INC. $11.6909/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997536423 CMS
ABBVIE INC. $7.0909/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997536425 CMS
Novartis Pharmaceuticals Corporation $14.5509/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992202121 CMS
ABBVIE INC. $20.8809/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997536421 CMS
ARGENX US, INC. $23.6409/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060431343 CMS
ARGENX US, INC. $7.0509/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060431345 CMS
Biogen, Inc. $9.4309/11/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012146731 CMS
Biogen, Inc. $14.4109/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012217305 CMS
Lundbeck LLC $16.4609/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032248425 CMS
ABBVIE INC. $8.5809/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997536419 CMS
Alexion Pharmaceuticals, Inc. $25.8009/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1024995531 CMS
Alnylam Pharmaceuticals Inc. $29.6809/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006169185 CMS
ABBVIE INC. $11.3808/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997536417 CMS
GENZYME CORPORATION $24.8208/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049802177 CMS
Lilly USA, LLC $18.2208/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031272911 CMS
ABBVIE INC. $11.9408/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997536415 CMS
Eisai Inc. $21.3808/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045413093 CMS
ABBVIE INC. $5.4208/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997536413 CMS
PFIZER INC. $23.1208/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050042353 CMS
BANNER LIFE SCIENCES, LLC $24.3308/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021113437 CMS
Jazz Pharmaceuticals Inc. $21.3908/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059085751 CMS
Otsuka America Pharmaceutical, Inc. $18.5508/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014425347 CMS
Takeda Pharmaceuticals U.S.A., Inc. $29.2108/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055413465 CMS
Biogen, Inc. $15.0908/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012257785 CMS
ABBVIE INC. $16.4808/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997536411 CMS
ABBVIE INC. $12.8208/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997536407 CMS
ABBVIE INC. $8.0208/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997536409 CMS
MDD US Operations, LLC $14.2308/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052879117 CMS
Amneal Pharmaceuticals LLC $13.9608/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053502031 CMS
UCB, Inc. $29.6808/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021481983 CMS
Biogen, Inc. $9.6308/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012185163 CMS
Genentech USA, Inc. $25.7308/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040304459 CMS
Kyowa Kirin, Inc. $27.7108/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026986963 CMS
Lilly USA, LLC $13.6607/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031270569 CMS
Novartis Pharmaceuticals Corporation $18.6007/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992202117 CMS
UCB, Inc. $23.2707/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021481971 CMS
SK Life Science, Inc. $31.9707/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1054725799 CMS
Biogen, Inc. $17.7607/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012161031 CMS
Jazz Pharmaceuticals Inc. $27.3607/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059085749 CMS
ARGENX US, INC. $4.4207/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060431337 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $33,929.55 258
PY2020 $26,458.58 175
PY2021 $23,808.38 193
PY2022 $6,194.08 151
PY2023 $3,559.32 195
PY2024 $5,919.36 276
PY2025 $4,993.10 247

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $126,456.93 40
PY2024 Principal investigator $49,291.29 15
PY2023 Principal investigator $34,954.63 9
PY2022 Principal investigator $37,927.07 7
PY2021 Principal investigator $92,335.73 18
PY2020 Principal investigator $72,203.12 19
PY2019 Principal investigator $16,673.39 12

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

40 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ARGENX US, INC. $250.00 12/19/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC No dispute reported 06/30/2026 1237154477
Principal investigator 1 ARGENX US, INC. $372.50 12/17/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1237154407
Principal investigator 1 ARGENX US, INC. $4,250.00 12/10/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1237154410
Principal investigator 1 ARGENX US, INC. $2,000.00 12/10/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1237154414
Principal investigator 1 ARGENX US, INC. $1,173.60 12/10/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1237154418
Principal investigator 1 ARGENX US, INC. $9.00 12/10/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1237154422
Principal investigator 1 ARGENX US, INC. $333.75 12/10/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1237154426
Principal investigator 1 ARGENX US, INC. $2,000.00 12/10/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1237154434
Principal investigator 1 ARGENX US, INC. $500.00 11/05/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC No dispute reported 06/30/2026 1237154465
Principal investigator 1 ARGENX US, INC. $1,000.00 11/05/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC No dispute reported 06/30/2026 1237154468
Principal investigator 1 ARGENX US, INC. $250.00 11/03/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
A randomized, double-blinded, placebo-controlled, phase 3, parallel-group design study evaluating the efficacy and safety of efgartigimod PH20 SC administered by prefilled syringe in adult participants with ocular myasthenia gravis No dispute reported 06/30/2026 1237154473
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $159.00 11/01/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA - STANFORD MEDICINE
A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223287809
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $135.00 11/01/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA - STANFORD MEDICINE
A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223287813
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $135.00 11/01/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA - STANFORD MEDICINE
A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223287815
Principal investigator 1 ARGENX US, INC. $1,641.51 10/17/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237154429
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,750.29 10/01/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Remibrutinib in Patients With Generalized Myasthenia Gravis, Followed by an Open-label Extension Phase No dispute reported 06/30/2026 1190305887
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,312.00 10/01/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA - STANFORD MEDICINE
A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223286009
Principal investigator 1 ARGENX US, INC. $2,250.00 09/03/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237154398
Principal investigator 1 ARGENX US, INC. $7,206.00 09/03/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237154402
Principal investigator 1 ARGENX US, INC. $11,030.76 08/22/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237154393
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,031.00 08/21/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223284481
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,120.00 08/21/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223284483
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 08/21/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223284485
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,052.00 08/21/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223284487
Principal investigator 1 ARGENX US, INC. $7,498.00 07/23/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
A randomized, double-blinded, placebo-controlled, phase 3, parallel-group design study evaluating the efficacy and safety of efgartigimod PH20 SC administered by prefilled syringe in adult participants with ocular myasthenia gravis No dispute reported 06/30/2026 1237154453
Principal investigator 1 ARGENX US, INC. $2,750.00 07/23/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
A randomized, double-blinded, placebo-controlled, phase 3, parallel-group design study evaluating the efficacy and safety of efgartigimod PH20 SC administered by prefilled syringe in adult participants with ocular myasthenia gravis No dispute reported 06/30/2026 1237154457
Principal investigator 1 ARGENX US, INC. $1,026.00 07/23/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
A randomized, double-blinded, placebo-controlled, phase 3, parallel-group design study evaluating the efficacy and safety of efgartigimod PH20 SC administered by prefilled syringe in adult participants with ocular myasthenia gravis No dispute reported 06/30/2026 1237154461
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $135.00 07/01/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223281936
Principal investigator 1 Janssen Research & Development, LLC $750.00 05/22/2025 Non-covered Recipient Entity
Nrlgy Associates Pa
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1175193619
Principal investigator 1 Janssen Research & Development, LLC $9,700.00 05/22/2025 Non-covered Recipient Entity
Nrlgy Associates Pa
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1175193768
Principal investigator 1 ARGENX US, INC. $19,690.52 05/09/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237154389
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $135.00 05/01/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES
A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223278742
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,312.00 04/01/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223277193
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $159.00 04/01/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223277198
Principal investigator 1 ARGENX US, INC. $10,188.75 03/12/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1237154445
Principal investigator 1 ARGENX US, INC. $3,217.50 03/12/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1237154450
Principal investigator 1 ARGENX US, INC. $6,238.00 03/05/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC No dispute reported 06/30/2026 1237154441
Principal investigator 1 Alexion Pharmaceuticals, Inc. $11,125.00 02/26/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES, PA
A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Generalized Myasthe No dispute reported 06/30/2026 1185538362
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $253.25 02/19/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF AVP-786 (DEUDEXTROMETHORPHAN HYDROBROMIDE [D6-DM]/QUINIDINE SULFATE [Q]) FOR THE TREATMENT OF AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMERS TYPE No dispute reported 06/30/2026 1225335547
Principal investigator 1 ARGENX US, INC. $2,317.50 01/29/2025 Non-covered Recipient Entity
NEUROLOGY ASSOCIATES PA
Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1237154437